Last reviewed · How we verify
CINRYZE 500 U
CINRYZE is a C1 esterase inhibitor (C1-INH) that replaces deficient or dysfunctional C1 inhibitor protein to prevent excessive bradykinin generation and control hereditary angioedema attacks.
CINRYZE is a C1 esterase inhibitor (C1-INH) that replaces deficient or dysfunctional C1 inhibitor protein to prevent excessive bradykinin generation and control hereditary angioedema attacks. Used for Hereditary angioedema (HAE) Types I and II — acute attack treatment and prophylaxis.
At a glance
| Generic name | CINRYZE 500 U |
|---|---|
| Sponsor | Shire |
| Drug class | C1 esterase inhibitor (C1-INH) replacement therapy |
| Target | C1 esterase inhibitor (C1-INH); contact system cascade regulation |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rare Genetic Disorders |
| Phase | Phase 3 |
Mechanism of action
Hereditary angioedema (HAE) results from deficiency or dysfunction of C1 esterase inhibitor, a regulatory protein in the contact system cascade. Without adequate C1-INH, uncontrolled activation of Factor XII and kallikrein leads to excessive bradykinin production, causing severe angioedema. CINRYZE provides exogenous C1-INH to restore normal regulation of this cascade and prevent acute swelling episodes.
Approved indications
- Hereditary angioedema (HAE) Types I and II — acute attack treatment and prophylaxis
Common side effects
- Thrombosis / thromboembolic events
- Headache
- Nausea
- Injection site reactions
- Hypersensitivity reactions
Key clinical trials
- Berinert (C1INH) vs Placebo for DGF/IRI (PHASE1, PHASE2)
- CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12 (PHASE2)
- Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE) (PHASE3)
- C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CINRYZE 500 U CI brief — competitive landscape report
- CINRYZE 500 U updates RSS · CI watch RSS
- Shire portfolio CI